Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris

Journal of the European Academy of Dermatology and VenereologyEarly View LETTER TO THE EDITOR Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris Ying Li, Ying Li orcid.org/0000-0002-4041-2646 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaoyuan Zhong, Xiaoyuan Zhong Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorDawei Huang, Dawei Huang orcid.org/0000-0003-0732-1467 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYuling Shi, Corresponding Author Yuling Shi [email protected] orcid.org/0000-0002-1273-7881 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China Correspondence Yangfeng Ding and Yuling Shi, Department of Dermatology, Shanghai Skin Disease Hospital; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Email: [email protected] and [email protected]Search for more papers by this authorYangfeng Ding, Corresponding Author Yangfeng Ding [email protected] Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China Correspondence Yangfeng Ding and Yuling Shi, Department of Dermatology, Shanghai Skin Disease Hospital; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Email: [email protected] and [email protected]Search for more papers by this author Ying Li, Ying Li orcid.org/0000-0002-4041-2646 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaoyuan Zhong, Xiaoyuan Zhong Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorDawei Huang, Dawei Huang orcid.org/0000-0003-0732-1467 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaSearch for more papers by this authorYuling Shi, Corresponding Author Yuling Shi [email protected] orcid.org/0000-0002-1273-7881 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China Correspondence Yangfeng Ding and Yuling Shi, Department of Dermatology, Shanghai Skin Disease Hospital; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Email: [email protected] and [email protected]Search for more papers by this authorYangfeng Ding, Corresponding Author Yangfeng Ding [email protected] Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China Correspondence Yangfeng Ding and Yuling Shi, Department of Dermatology, Shanghai Skin Disease Hospital; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Email: [email protected] and [email protected]Search for more papers by this author First published: 30 March 2024 https://doi.org/10.1111/jdv.19992 Ying Li, Xiaoyuan Zhong and Dawei Huang contributed equally to this work Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Blicharz L, Czuwara J, Rudnicka L, Torrelo A. Autoinflammatory keratinization diseases-the concept, pathophysiology, and clinical implications. Clin Rev Allergy Immunol. 2023; 65: 377–402. 10.1007/s12016-023-08971-3 Web of Science®Google Scholar 2Iznardo H, Puig L. Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. Curr Opin Rheumatol. 2022; 34: 225–234. 10.1097/BOR.0000000000000882 PubMedWeb of Science®Google Scholar 3Sood S, Akuffo-Addo E, Yeung J, Mufti A. Biologic treatment options for pityriasis rubra pilaris: an evidence-based systematic review. J Am Acad Dermatol. 2023; 89: 1306–1308. 10.1016/j.jaad.2023.08.057 Web of Science®Google Scholar 4Dhar S, Datta S, De A. Use of Janus kinase inhibitors in atopic dermatitis – an update. Indian J Dermatol Venereol Leprol. 2023; 1–8. 10.25259/IJDVL_14_2023 Google Scholar 5Zhang L, Guo L, Wang L, Jiang X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – a network meta-analysis. J Eur Acad Dermatol Venereol. 2022; 36: 1937–1946. 10.1111/jdv.18263 CASPubMedWeb of Science®Google Scholar 6Li Y, Chen Z, He M, Tan X, Nie S, Zeng Y, et al. Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.19762 10.1111/jdv.19762 Web of Science®Google Scholar 7Song EJ, Al-Saedy MA, Bouché N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep. 2023; 35: 112–114. 10.1016/j.jdcr.2023.03.004 Google Scholar 8Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: a case report. SAGE Open Med Case Rep. 2023; 11:2050313X231160927. 10.1177/2050313X231160927 Web of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation